ClinicalTrials.govpublic full text
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
spondylitis, ankylosing, ain457, ankylosing spondylitis, chronic inflammatory disease, inflammatory back pain, secukinumab, self-injection, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 837021
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.